Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Michael C. Cox"'
Autor:
Ulrike Gerdemann, Steve Smith, Michael C. Cox, A. Lindsay Frazier, Peter M. Anderson, Sandya Govinda Raju, Julia Glade Bender, S. Michael Rothenberg, Alberto S. Pappo, Michael V. Ortiz, Dahlia Henry, Stéphanie Proust
Publikováno v:
JCO Precision Oncology
Autor:
Alison Patterson, Vincent A. Miller, Theodore W. Laetsch, Steven J. Smith, Steve Megison, Matthew Cooke, Lawrence W. Wu, Siraj M. Ali, Michael C. Cox, Dean Pavlick, Andrew A. Martin, Caitlyn Ambrose, Lee A. Albacker, Tara Pavlock, Anne Post, Veena Rajaram
Publikováno v:
JCO Precision Oncology
Autor:
Alberto S. Pappo, Cornelis M. van Tilburg, Catherine M. Albert, Steven G. DuBois, Todd Eary, Michael C. Cox, Leo Mascarenhas, Shannon Ibabekci, Frank M. Balis, Theodore W. Laetsch, Stephen M. Rothenberg, Sheri L. Spunt, Daniel A. Morgenstern, Samara L. Potter, Raquel Hladun, David S. Ziegler, Hope Qamoos, Brian Turpin, Michela Casanova, Julia Glade Bender
Publikováno v:
Journal of Clinical Oncology. 37:TPS10066-TPS10066
TPS10066 Background: Genomic alterations in the RET kinase, including gene fusions and activating point mutations, are implicated in the pathogenesis of lung, thyroid, sarcoma and other cancers in both chidren and adults. Currently available multikin
Autor:
Steven G. DuBois, Anna F. Farago, Birgit Geoerger, Juneko E. Grilley-Olson, Nora Ku, Shivani Nanda, Davendra Sohal, David S. Hong, Alexander Drilon, Barrett H. Childs, David S. Ziegler, Cornelis M. van Tilburg, Francois P. Doz, Michael C. Cox
Publikováno v:
Journal of Clinical Oncology. 37:2006-2006
2006 Background: TRK fusions are oncogenic drivers of a variety of cancers, many of which can involve the central nervous system (CNS). Larotrectinib is an FDA-approved selective TRK inhibitor for the treatment of TRK fusion cancer (Drilon et al, NEJ
Autor:
Theodore W. Laetsch, Noah Federman, Barrett H. Childs, Leo Mascarenhas, Catherine M. Albert, Alberto S. Pappo, Shivani Nanda, Brian Turpin, Birgit Geoerger, Steven G. DuBois, Michela Casanova, Sheri L. Spunt, Neerav Shukla, Daniel Orbach, Stefan S. Bielack, Hope Qamoos, Ramamoorthy Nagasubramanian, Cornelis M. van Tilburg, Michael C. Cox
Publikováno v:
Journal of Clinical Oncology. 37:10010-10010
10010 Background: TRK fusions involving NTRK1, NTRK2, and NTRK3 genes have been identified in a broad range of pediatric and adult malignancies. Larotrectinib, a highly-selective oral TRK inhibitor, was well tolerated and showed encouraging antitumor
Autor:
Dahlia Henry, Alberto S. Pappo, Julia Glade Bender, Ulrike Gerdemann, Michael V. Ortiz, Hyoung Jin Kang, Steven J. Smith, Young Ah Lee, A. Lindsay Frazier, Michael C. Cox, Sandya Govinda Raju, Stephen M. Rothenberg
Publikováno v:
Journal of Clinical Oncology. 37:10045-10045
10045 Background: Genomic alterations of RET kinase, including chromosomal fusions and activating point mutations, have been identified as oncogenic drivers in pediatric and adult cancers. Multikinase inhibitors have modest activity against RET-alter
Publikováno v:
Journal of Clinical Oncology. 22:2489-2503
PurposeInterest in the use of herbal products has grown dramatically in the Western world. Recent estimates suggest an overall prevalence for herbal preparation use of 13% to 63% among cancer patients. With the narrow therapeutic range associated wit
Autor:
Leo Mascarenhas, Alberto S. Pappo, Steven G. DuBois, Douglas S. Hawkins, Scott Cruickshank, Michael C. Cox, Noah Federman, Mark Reynolds, Brian Turpin, Theodore W. Laetsch, Steven J. Smith, Ramamoorthy Nagasubramanian
Publikováno v:
Journal of Clinical Oncology. 35:10510-10510
10510 Background: Larotrectinib is the first selective small-molecule inhibitor of TRKA, B, and C in clinical development. Data from the adult phase I trial demonstrate prolonged responses in patients (pts) with TRK fusions and a favorable tolerabili
Autor:
Steven G. DuBois, Brian Turpin, Alexander Drilon, Ulrik Lassen, Marcia S. Brose, Douglas S. Hawkins, Nora Ku, Theodore W. Laetsch, Shivaani Kummar, Valentina Boni, George D. Demetri, Wafik S. El-Deiry, Scott Cruickshank, Michael C. Cox, Anna F. Farago, David M. Hyman, Afshin Dowlati, Alberto S. Pappo, Ramamoorthy Nagasubramanian, David S. Hong
Publikováno v:
Journal of Clinical Oncology. 35:LBA2501-LBA2501
LBA2501 Background: Larotrectinib is the first selective small-molecule pan-TRK inhibitor. TRK fusions appear oncogenic independent of tumor lineage, are widely distributed across cancers, and affect all ages. We present an integrated dataset from 3
Autor:
Alberto S. Pappo, Steven G. DuBois, Lia Donahue, Theodore W. Laetsch, Mark Reynolds, Leo Mascarenhas, Michael C. Cox, Steven J. Smith, Scott Cruickshank, Ramamoorthy Nagasubramanian
Publikováno v:
Journal of Clinical Oncology. 34:TPS10583-TPS10583
TPS10583Background: The TRK family of neurotrophin receptors, TRKA, TRKB, and TRKC (encoded by NTRK1, NTRK2, and NTRK3 genes, respectively) and their neurotrophin ligands regulate growth, different...